H1B Report
Side-by-side comparison

AMNEAL PHARMACEUTICALS OF NY LLC vs WIPRO LIMITED

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
AMNEAL PHARMACEUTICALS OF NY LLC
NYRank #FEIN 26-2478140
Entity B
WIPRO LIMITED
NJRank #6FEIN 98-0154401

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricAMNEAL PHARMACEUTICALS OF NY LLCWIPRO LIMITED
Total filings41972,392
Certified %94.75%91.61%
Denied %0.24%0.37%
Withdrawn %3.10%1.37%
Cert-withdrawn %1.91%6.64%
Rank#6
Active yearsFY2010–FY2026FY2010–FY2026
Worksite stateNYNJ

Outcomes — AMNEAL PHARMACEUTICALS OF NY LLC

DOL case-status mix.

Outcome breakdown: Certified 94.8%, Cert-withdrawn 1.9%, Withdrawn 3.1%, Denied 0.2%
Outcome breakdown
OutcomeShare
Certified94.8%
Cert-withdrawn1.9%
Withdrawn3.1%
Denied0.2%
Certified94.8%
Cert-withdrawn1.9%
Withdrawn3.1%
Denied0.2%

Outcomes — WIPRO LIMITED

DOL case-status mix.

Outcome breakdown: Certified 91.6%, Cert-withdrawn 6.6%, Withdrawn 1.4%, Denied 0.4%
Outcome breakdown
OutcomeShare
Certified91.6%
Cert-withdrawn6.6%
Withdrawn1.4%
Denied0.4%
Certified91.6%
Cert-withdrawn6.6%
Withdrawn1.4%
Denied0.4%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

AMNEAL PHARMACEUTICALS OF NY LLC
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY201031
FY201136
FY201249
FY201333
FY201429
FY201534
FY201636
FY201733
FY201836
FY201940
FY20202
FY20211
FY20220
FY20232
FY202415
FY202521
FY202621
WIPRO LIMITED
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20103,039
FY20113,025
FY20127,031
FY20136,574
FY20148,104
FY201511,824
FY201610,254
FY20175,012
FY20186,067
FY20194,154
FY202094
FY2021128
FY202297
FY2023554
FY20242,296
FY20252,289
FY20261,850

Top 5 occupations — AMNEAL PHARMACEUTICALS OF NY LLC

Top 5 occupations — WIPRO LIMITED

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.